Ferring Pharmaceuticals bolsters global gene therapy supply chain with European manufacturing facility
Saint-Prex, Switzerland: This milestone represents significant progress in Ferring’s manufacturing capabilities to meet anticipated growth in demand for Adstiladrin® (nadofaragene firadenovec-vncg), a gene therapy for people with non-muscle invasive bladder cancer (NMIBC). With bladder cancer now the ninth most diagnosed cancer around the world 1, securing the global […]
Ferring Demonstrates Effectiveness of a Treat-to-Target Approach in Mild-to-Moderate Ulcerative Colitis in First Major Study
Saint-Prex, Switzerland: OPTIMISE study found a treat-to-target (T2T) management strategy in people with mild-to-moderate ulcerative colitis (M2M UC) being treated with 5-aminosalicylic acid (5-ASA; mesalazine) utilising faecal calprotectin (FC) home monitoring over 12 months achieved a significantly higher rate of endoscopic and clinical remission compared to a symptom-based approach […]